
    
      Primary objective of the study is to assess whether early evolocumab administration reduces
      infarct size in patients with STEMI undergoing primary PCI.

      At least 150 patients will be enrolled to investigate the efficacy and safety of evolocumab
      administration in the acute phase of STEMI.

      Patients will be followed for 1 year after the enrollment.
    
  